Base Demand Forecast. v15, prepared in Reach every child

Similar documents
GAVI S CONTINUED ROLE IN YELLOW FEVER CONTROL

UNICEF IPV Tender: Demand Forecast UNICEF Bidder s Conference WHO, Geneva 11 October 2013

Measles Containing Vaccines. UNICEF Supply Division Industry Consultation Meeting January 2012

Managing constrained vaccine supply: prevention and remediation Lessons learned and ways forward DVCMN Annual Meeting October Bangkok,

UNICEF ZIKA Diagnostics VACCINES Demand Forecast. Jorgen Kofoed UNICEF SD

GAVI Role in IPV Introductions

TODAY S VACCINATION ECOSYSTEM STATUS MARKET-SHAPING PRINCIPLES, PRACTICE, IMPACT AND LESSONS LEARNT GAVI PERSPECTIVE

Information for Access

POLIO ERADICATION AND POST-CERTIFICATION STRATEGY

Report to the Board 6-7 June 2018

Polio and routine immunisation Alan Brooks

GAVI S VACCINE INVESTMENT STRATEGY

TYPHOID CONJUGATE VACCINE SUPPORT WINDOW

Gavi Secretariat Update: Progress, priorities and strategies

Gavi s strategic framework 22 June 2016

Safe Injection Equipment

Rotavirus Vaccine. Supply and Procurement Roadmap. The Market Shaping Goal. Public Summary. Rotavirus Supply and Procurement Roadmap UPDATE 2016

Report to the. GAVI Alliance Board June 2013

Meningitis Vaccine Procurement

GAVI, THE VACCINE ALLIANCE

UNICEF Procurement Advancements DCVMN Annual Meeting Hanoi, Vietnam October 2013

Rotavirus Vaccine: Supply & Demand Update. UNICEF Supply Division

Oral Polio Vaccine Supply Outlook. UNICEF Supply Division

How does Gavi make vaccine investment decisions?

Vaccine Security UNICEF Vaccine Procurement Overview. Supplier meeting UNICEF Supply Division 3-4 April 2008 Rob Matthews

Paradigm shift: from dependency to country ownership Seth Berkley, MD Chief Executive Officer of the GAVI Alliance

Polio & routine immunisation Alan Brooks

Tendering to support new vaccine introduction in Middle Income Countries. UNICEF Supply Division Presentation to Manufacturers 28 November 2012

Update on Polio Vaccine Supply

Inaugural Keynote Lecture: Contributions of Gavi and DCVMN to the global vaccine markets

Yellow Fever Vaccine: Current Outlook. UNICEF Supply Division

Gavi s Vaccine Investment Strategy

Tendering to support new vaccine introduction in Middle Income Countries. UNICEF Supply Division Presentation to Partners 28 November 2012

Gavi, the Vaccine Alliance - Health System and Immunisation Strengthening (HSIS) Support Framework

What is to be done to respond to country needs and comply with WHA and SAGE recommendations?

Update from GAVI Aurelia Nguyen

Perspectives on Ensuring Access to Vaccines in Lower Income Countries

What are the outputs? What is generated by whom? Decade of Vaccine Economics (DOVE) 18/07/2014

Yellow Fever Vaccine

Pentavalent Market. UNICEF/UN074464/Lister. UNICEF SUPPLY DIVISION 2018 Vaccine Industry Consultation

HPV Vaccine Lessons Learned & New Ways Forward

Gavi Alliance Strategy : Goal level indicators and disease dashboard

GAVI Alliance. Aurelia Nguyen, Director Policy & Market Shaping. IPC Meeting 30 May 2013

UNICEF s perspective. WHO Informal Consultation to develop further guidance on vaccines for the UNEP-convened INC4 Geneva, 3-4 April 2012

Gavi s Sustainability and Transition Approach

Report to the Board 7-8 December 2016

MARKET UPDATE: ROUTINE VACCINE INTRODUCTIONS PCV HPV ROTA

Report to the Board June 2015

Progress with IPV introduction Polio Partners Group PPG 16 June 2014

Global Vaccine Market Report

REVIEW OF DECISIONS. BOARD MEETING 6-7 June 2018, Geneva. Reach every child

Gavi initiatives for improving vaccine supply

Overview of Measlescontaining. through UNICEF. Overview of [VACCINE] through UNICEF

International Coordinating Group for vaccine provision. Emergency Vaccine Stockpiles

Report to the. GAVI Alliance Board November 2013

Meningococcal Vaccine ICG stockpile 2016

Update on polio vaccine supply & forecast

Polio post-certification strategy

SUCCESSFULLY TRANSITIONING NIGERIA FROM GAVI SUPPORT

Vaccine Introduction & Uptake Timing Benchmark Project

The new WHO global injection safety policy and campaign

VIEW-hub Report: Global Vaccine Introduction and Implementation

EPF s response to the European Commission s public consultation on the "Summary of Clinical Trial Results for Laypersons"

Challenges of use of cholera vaccines in Haiti and the Americas

MALARIA VACCINE PILOTS

Vaccines Supply Shortages Challenges & Opportunities

Managing the Gavi transition

Report to the Board. Typhoid vaccines: WHO Position paper. Weekly epidemiological record. 2008; 6: ibid

The Financial Sustainability of New Vaccine Introduction in the Poorest Countries :

GAVI partners Forum, Dar es Salaam, Tanzania December 5-7, 2012

Protecting people against known and emerging infectious diseases globally

New Delhi International Ministerial Conference on Avian and Pandemic Influenza Dec 4-6th, 2007

Procurement Strategy for Rotavirus and Pneumococcal Conjugate Vaccines. Supplier meeting UNICEF Supply Division 3-4 April 2008 Ann Ottosen

TT Procured by UNICEF

CONSOLIDATED COMMENTS FROM THE PUBLIC CONSULTATION ON EXTERNALITIES OF GAVI MARKET SHAPING ACTIVITIES

Gavi s private sector engagement approach

Responding to the SAGE Recommendations on Middle Income Countries Since Sarah Schmitt WHO Consultant

Access to affordable vaccines in Emergency and Humanitarian Response June 20, 2016

Measles Containing Vaccines

Pneumococcal Conjugate Vaccine: Current Supply & Demand Outlook. UNICEF Supply Division

VIEW-hub Report: Global Vaccine Introduction and Implementation

Strengthening efforts to improve access to and affordability of medicines and technologies in the prevention and control of NCDs

Gavi, the Vaccine Alliance: Supply and Procurement Strategy

GAVI Alliance Demand-side Innovation Policies

Market Update. Human Papillomavirus vaccine (HPV) Vaccine Industry Consultation November 2016

Government of Bangladesh

Guide on Access to the Yellow Fever ICG Stockpile. Emergency Campaigns. International Coordinating Group on Vaccine. Geneva, Switzerland 2012

Measles-Containing Vaccines: Supply & Demand Outlook. UNICEF Supply Division

Report to the Board June 2016

VERSION APPROVAL PROCESS NUMBER 1.0 Nina Schwalbe, Managing Director, Policy and Performance

VACCINE MARKETS OVERVIEW SESSION

Presentation to 13th Annual General Meeting of the DCVMN UNICEF Vaccine Forecasting

Vaccine Decision-Making

EXTERNAL EVALUATION OF THE INTERNATIONAL COORDINATING GROUP ON VACCINE PROVISION (ICG) MECHANISM

Establishing a cholera stockpile: What do we need? Alejandro Costa Epidemic Readiness and Intervention

UPDATE ON GAVI. Julian Lob-Levyt. Global Immunisation Meeting New York, February 2009

Report to the Board 6-7 June 2018

MI4A - Market Information for

THE SITUATION OF YELLOW FEVER IN THE AFRICAN REGION: THE PLAN TO END YF EPIDEMICS IN 2026

UNICEF 2017 VACCINE INDUSTRY CONSULTATION October 2017 UNICEF Supply Division, Oceanvej 10-12, 2150, Nordhavn, Copenhagen, Denmark

Transcription:

Base Demand Forecast v15, prepared in 2017 Reach every child www.gavi.org December, 2017

Introduction This is the second publication of the Base Demand Forecast that describes the volume projections that inform Gavi s financial forecast and impact projections. This publication was prepared in 2017 and aligns with the v15 financial forecast cycle. The publication is intended to improve the transparency and timeliness of demand forecasts shared with Gavi partners, industry and the public. The Base Demand Forecast is published annually following Gavi s 4 th quarter Board meeting where the financial forecast is reviewed. In general, the forecast will be published in December or January each year. This publication includes tables describing volumes associated with two different country scopes. The first table summarizes volumes for forecasts that generally considered the 73 countries that were eligible for Gavi support as of 2011. This set of countries is labelled Gavi 73. The second table summarizes actual and forecasted volumes that considered 65 countries, defined as the same Gavi 73 countries but excluding India, Indonesia, Ukraine and five Pan American Health Organization (PAHO) countries. The Gavi 65 country scope is designed to help improve the consistency across actuals and forecasted periods given that actual shipments reported by UNICEF are often limited in scope to the 65 countries. The volumes presented include doses regardless of actual or projected funding source. The figures include doses projected to be funded by Gavi and doses co-financed by supported countries. In addition, the volumes include doses projected to be fully self-financed by countries that have transitioned from Gavi support, as well as estimated demand for programmes that introduce without Gavi support. Volumes reflect supply constraints where relevant. There are a number of important nuances in the volume forecasts that have been footnoted to the extent possible. In general, the base demand forecast publication seeks to find a balance on describing some of the key complexities while still keeping this publication relatively simple for its intended purpose. Nevertheless, we recognize there may be additional details and explanation that will be required for some audiences and purposes. Users of this new publication can contact forecast@gavi.org if they require further guidance or information. Feedback and suggestions for improvement on this new demand forecast publication are also welcomed. Please send comments to forecast@gavi.org.

Total Gavi 73 Volume by Vaccine, doses, millions Sources Forecasted doses are from the demand forecast used to inform the v15 Gavi financial forecast reviewed by the Gavi Board at its November 2017 meeting Notes The figures above includes doses funded by Gavi, co-financed doses funded by countries, doses fully self-financed by transitioned countries, and doses for countries introducing without Gavi support. The country scope considered for MenA, YF, and JE are limited to the geographies where these regional programs focus. Men A and YF rows do not account for volumes associated with stockpiles. Gavi support for IPV is based on earmarked funding for the 2014-2019 period. This version of the forecast assumes the use of fractional IPV doses in some countries based on the April 2017 IPV SAGE recommendations. TCV is not included in this table as the v15 forecast focussed on the Gavi 65; a Gavi 73 view of TCV will be included in the next version

Total Gavi 65 Volume by Vaccine, doses, millions Sources Actual volumes are based on shipment reports published by UNICEF Supply Division. Forecasted volumes are from the demand forecast aligned with the v15 Gavi financial forecast reviewed by the Gavi Board at its November 2017 meeting Notes The figures above includes doses funded by Gavi, co-financed doses funded by countries, doses fully self-financed by transitioned countries, and doses for countries introducing without Gavi support. The scope of countries considered in actuals and forecasted values is generally 65 countries: the Gavi 73 less India, Indonesia, Ukraine, and five PAHO countries. The country scope considered for MenA, YF, and JE are limited to the geographies where these regional programs focus. Men A and YF rows do not account for volumes associated with stockpiles Actual volumes should be interpreted as minimums in some vaccines where there is significant procurement through channels other than UNICEF Gavi support for IPV is based on earmarked funding for the 2014-2019 period. This version of the forecast assumes the use of fractional IPV doses in some countries based on the April 2017 IPV SAGE recommendations.

5 Thank you Reach every child www.gavi.org